Compare · PM vs SGTX
PM vs SGTX
Side-by-side comparison of Philip Morris International Inc (PM) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PM and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM is the larger of the two at $302.25B, about 5197.1x SGTX ($58.2M).
- PM has hit the wire 7 times in the past 4 weeks while SGTX has been quiet.
- PM has more recent analyst coverage (25 ratings vs 8 for SGTX).
- Company
- Philip Morris International Inc
- Sigilon Therapeutics Inc.
- Price
- $195.79+0.89%
- $22.53-2.57%
- Market cap
- $302.25B
- $58.2M
- 1M return
- -2.14%
- -
- 1Y return
- +17.46%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 8
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Sigilon Therapeutics Inc.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Latest PM
- Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Altria Announces Arrangement with Philip Morris International to Enhance Operational Efficiency
- Philip Morris International Announces Contract Manufacturing Collaboration with Altria
- FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review
- PMI U.S. Names Five Artists Shaping Modern American Culture for the ZYN America250 Art Series
- New insider Andolina Massimo claimed ownership of 71,588 shares (SEC Form 3)
- SEC Form 25-NSE filed by Philip Morris International Inc
- SEC Form 10-Q filed by Philip Morris International Inc
- BTIG Research initiated coverage on Philip Morris International with a new price target
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SGTX
- SEC Form SC 13G/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Sigilon Therapeutics Inc.
- SEC Form EFFECT filed by Sigilon Therapeutics Inc.
- SEC Form 4 filed by Flagship Ventures Fund V General Partner Llc
- Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
- SEC Form SC 13D/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 4: Eli Lilly & Co bought $25,639,916 worth of shares (1,718,493 units at $14.92)
- Lilly Completes Acquisition of Sigilon Therapeutics
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.